Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

25.07 +0.12 (+0.48%)
Streaming Delayed Price Updated: 10:20 AM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024 ↗
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
4 Analysts Assess Denali Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 ↗
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Denali Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Denali Therapeutics ↗
 
Via Benzinga
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
News headline image
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces $500 million Private Placement Equity Financing
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
News headline image
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth ↗
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
Via InvestorPlace
News headline image
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.